# Patricia LoRusso

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patricia-lorusso/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,063 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 87 |
| i10-index | 391 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5064953304 |
| ORCID iD | https://orcid.org/0000-0001-7144-036X |
| Works | 1,281 |

## Researcher papers

- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/quantitative-assessment-of-the-heterogeneity-of-pd-l1-expression-in-non-small/)
- [Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study](https://scholariq.org/papers/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in/)
- [A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors](https://scholariq.org/papers/a-phase-i-ii-study-of-the-oral-parp-inhibitor-rucaparib-in-patients-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.